Jove
Visualize
Contact Us

Related Experiment Videos

[Therapeutic monoclonal antibodics].

J-F Bach1

  • 1Inserm U580, Hôpital Necker-Enfants Malades, 161, rue de Sèvres, F 75015 Paris. bach@necker.fr

Annales Pharmaceutiques Francaises
|November 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Causality and complex disease: The example of multiple sclerosis.

Revue neurologique·2017
Same author

Causality and complex disease: The example of multiple sclerosis.

Revue neurologique·2017
Same author

Filaggrin gene loss-of-function variants modify the effect of breast-feeding on eczema risk in early childhood.

Allergy·2016
Same author

Early weaning is beneficial to prevent atopic dermatitis occurrence in young children.

Allergy·2016
Same author

Casein-specific IL-4- and IL-13-secreting T cells: a tool to implement diagnosis of cow's milk allergy.

Allergy·2014
Same author

Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2012
Same journal

[Artificial Intelligence in the Pharmaceutical Industry: Governance, Quality, and Regulatory Challenges].

Annales pharmaceutiques francaises·2026
Same journal

No evidence of significant natural environmental exposure to arsenic for Napoleon I on the island of Saint Helena (1815-1821).

Annales pharmaceutiques francaises·2026
Same journal

EFFECTS OF GLP-1 RECEPTOR AGONISTS ON PERIODONTAL TISSUE: AN INTERDISCIPLINARY EVIDENCE MAPPING - SCOPING REVIEW.

Annales pharmaceutiques francaises·2026
Same journal

Regulatory non-compliance of parallel imported medicines in Kenya and implications for public health: Evidence from Nairobi County.

Annales pharmaceutiques francaises·2026
Same journal

Prostaglandin analogues in cosmetic products formulated for eyelash lengthening.

Annales pharmaceutiques francaises·2026
Same journal

Mechanistic and thermodynamic evaluation of sodium citrate-mediated hydrotropism for the biopharmaceutical optimization of BCS Class II drug atorvastatin calcium.

Annales pharmaceutiques francaises·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Monoclonal antibodies, developed after hybridoma technology, offer targeted therapies for various diseases. Recent studies show anti-CD3 antibodies can restore self-tolerance in new diabetics, inducing remission within a week.

Area of Science:

  • Immunology
  • Biotechnology
  • Pharmacology

Context:

  • The discovery of hybridomas in 1975 paved the way for monoclonal antibody (mAb) therapeutics.
  • Early therapeutic applications, like anti-CD3 for graft rejection, faced development delays.
  • Genetic engineering enabled antibody humanization and development of fully human antibodies via phage display.

Purpose:

  • To review the evolution and therapeutic applications of monoclonal antibodies.
  • To highlight the development of humanized and fully human antibodies.
  • To showcase the efficacy of mAbs in areas where conventional treatments fall short.

Summary:

  • Monoclonal antibodies are engineered proteins targeting specific molecules, revolutionizing treatment for transplantation, infections, cancer, and autoimmune diseases.

Related Experiment Videos

  • Therapeutic antibodies have evolved from murine to humanized and fully human forms, enhancing safety and efficacy.
  • Recent research demonstrates anti-CD3 mAbs can restore self-tolerance in type 1 diabetes, inducing rapid remission.

    • Impact:

    • Monoclonal antibodies provide highly specific and effective treatments, overcoming limitations of conventional therapies.
    • The fine specificity of mAbs allows for diverse targeting strategies, including signaling modulation.
    • Demonstrated success in restoring self-tolerance in type 1 diabetes showcases novel therapeutic potential.